Phase 1b trial on the safety, tolerability and immunogenicity of anti‐amyloid vaccine ALZ‐101 in subjects with MCI or mild AD

Background ALZ‐101 is a vaccine comprised of stabilised oligomeric Aβ42 that stimulates a humoral immune response primarily targeting a toxic, low‐abundant oligomeric form of Aβ. Part A of a clinical Phase 1b trial (ALZ‐C‐001; NCT05328115) was recently concluded with the objectives to assess the saf...

Full description

Bibliographic Details

Published in:	Alzheimer's & dementia Vol. 20; no. S8
Main Authors:	Zetterberg, Henrik, Rinne, Juha O., Sandberg, Anders, Lovró, Zsófia, Scheinin, Mika, Pierrou, Stefan, Harting, Kirsten
Format:	Journal Article
Language:	English
Published:	Hoboken John Wiley and Sons Inc 01.12.2024
Subjects:	Drug Development
ISSN:	1552-5260, 1552-5279
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!